Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database

• Published in: Andrology (Oxford) 2023-10, Vol.11 (7), p.1408-1417
• Main Authors: Lui, Jason L, Shaw, Nathan M, Abbasi, Behzad, Hakam, Nizar, Breyer, Benjamin N
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Confidence intervals; Drug efficacy; Erectile Dysfunction - chemically induced; Erectile Dysfunction - drug therapy; Genital diseases; Humans; Male; Melanoma; Melanoma - chemically induced; Melanoma - drug therapy; Melanoma, Cutaneous Malignant; Penis; Pharmacists; Pharmacovigilance; Phosphodiesterase 5 Inhibitors - therapeutic use; Priapism; Sexual disorders; Sildenafil Citrate - adverse effects; Skin cancer; Tadalafil - adverse effects; Vardenafil Dihydrochloride - adverse effects; World Health Organization
• ISSN: 2047-2919; 2047-2927
• DOI: 10.1111/andr.13430

Despite their efficacy and general safety, rare but devastating adverse drug reactions have been associated with phosphodiesterase type 5 inhibitors. To determine the safety profile of oral phosphodiesterase type 5 inhibitors with a particular focus on priapism and malignant melanoma. In this case-non-case study, we queried the individual case safety reports for phosphodiesterase type 5 inhibitors within the World Health Organization global database of individual case safety reports (VigiBase) between 1983 and 2021. We included all individual case safety reports for sildenafil, tadalafil, vardenafil, and avanafil in men. For comparison, we also extracted the safety data from the Food and Drug Administration trials for these drugs. We assessed the safety profile of phosphodiesterase type 5 inhibitors by disproportionality analysis by measuring reporting odds ratio for their most commonly reported adverse drug reactions, once for all phosphodiesterase type 5 inhibitor reports and once for reports of oral phosphodiesterase type 5 inhibitor use in adult men (≥18 years old) with sexual dysfunction. A total of 94,713 individual case safety reports for phosphodiesterase type 5 inhibitors were extracted. A total of 31,827 individual case safety reports were identified relating to adult men taking oral sildenafil, tadalafil, vardenafil, or avanafil for sexual dysfunction. The most common adverse drug reactions included poor drug efficacy (42.5%), headache (10.4% vs. 8.5%-27.6% [Food and Drug Administration]), abnormal vision (8.4% vs. ≤4.6% [Food and Drug Administration]), flushing (5.2% vs. 5.1%-16.5% [Food and Drug Administration]), and dyspepsia (4.2% vs. 3.4%-11.1% [Food and Drug Administration]). Priapism showed significant signals for sildenafil (reporting odds ratio = 13.81, 95% confidence interval: 11.75-16.24), tadalafil (reporting odds ratio = 14.54, 95% confidence interval: 11.56-18.06), and vardenafil (reporting odds ratio = 14.12, 95% confidence interval: 8.36-22.35). Comparing with other medications in VigiBase, sildenafil (reporting odds ratio = 8.73, 95% confidence interval: 7.63-9.99) and tadalafil (reporting odds ratio = 4.25, 95% confidence interval: 3.19-5.55) had significantly higher reporting odds ratios for malignant melanoma. Phosphodiesterase type 5 inhibitors show significant signals correlating with priapism among a large international cohort. Further clinical study is needed to elucidate whether this is from proper or inappropriate use o